Insider Transactions in Q1 2025 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
679
-0.71%
|
$5,432
$8.99 P/Share
|
|
Mar 04
2025
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,572
-2.25%
|
$20,576
$8.99 P/Share
|
|
Mar 01
2025
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
136,000
+11.21%
|
-
|
|
Mar 01
2025
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+24.99%
|
-
|
|
Mar 01
2025
|
Edward J Dulac Iii EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,200
+29.37%
|
-
|
|
Mar 01
2025
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,200
+24.82%
|
-
|
|
Mar 01
2025
|
Michael P Dube VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+19.01%
|
-
|
|
Mar 01
2025
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.89%
|
-
|
|
Mar 01
2025
|
Birgit C Schultes EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,600
+26.33%
|
-
|
|
Jan 29
2025
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-1.34%
|
$2,385
$9.97 P/Share
|
|
Jan 03
2025
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
26,807
-2.77%
|
$321,684
$12.18 P/Share
|
|
Jan 03
2025
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,502
-9.8%
|
$78,024
$12.18 P/Share
|
|
Jan 03
2025
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,557
-9.83%
|
$114,684
$12.18 P/Share
|
|
Jan 03
2025
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
7,074
-8.67%
|
$84,888
$12.18 P/Share
|
|
Jan 03
2025
|
Michael P Dube VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,372
-2.92%
|
$16,464
$12.18 P/Share
|
|
Jan 03
2025
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,966
-10.38%
|
$107,592
$12.18 P/Share
|
|
Jan 03
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,422
-10.38%
|
$89,064
$12.18 P/Share
|
|
Jan 02
2025
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
556
-0.77%
|
$6,672
$12.03 P/Share
|
|
Jan 01
2025
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,850
+0.8%
|
-
|
|
Jan 01
2025
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+3.9%
|
-
|
|
Jan 01
2025
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,189
+3.18%
|
-
|